sellModerate cluster of 7
Ramiro Sanchez sold $421k of CERE
Chief Medical Officer at Cerevel Therapeutics Holdings, Inc.. 10,152 shares at an average of $41.42, traded Dec 20, 2023, filed Dec 21, 2023.
Warning score
41Value
$421k
10,152 shares
Holdings after
14,673
-41% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- +16Trade size$421k at market
- +10Share of holdings soldSold 41% of holdings
- +15Cluster7 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0000950170-23-072370, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 19, 2023 | MOption exercise Common Stock | +24,825 | - | - | 24,825 | Dec 21, 2023 |
| Dec 20, 2023 | SOpen-market sale Common Stock | -10,152 | $41.42 | $421k | 14,673 | Dec 21, 2023 |
| Dec 19, 2023 | MOption exercise Restricted Stock Unitsderivative | -24,825 | $0.00 | $0 | 0 | Dec 21, 2023 |
Related signals
Other insiders at Cerevel Therapeutics Holdings, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | Cerevel Therapeutics Holdings, Inc. | N Anthony Coles director | $1.0M 25,000 shares | -49% | |
| 25Weak | Cerevel Therapeutics Holdings, Inc. | N Anthony Coles director | $2.0M 50,000 shares | -76% | |
| 25Weak | Cerevel Therapeutics Holdings, Inc. | N Anthony Coles director | $2.1M 50,000 shares | -76% | |
| 25Weak | Cerevel Therapeutics Holdings, Inc. | N Anthony Coles director | $2.1M 50,000 shares | -76% | |
| 25Weak | Cerevel Therapeutics Holdings, Inc. | N Anthony Coles director | $2.1M 50,000 shares | -76% | |
| 25Weak | Cerevel Therapeutics Holdings, Inc. | N Anthony Coles director | $2.1M 50,000 shares | -76% | |
| 23Weak | Cerevel Therapeutics Holdings, Inc. | N Anthony Coles director | $104k 2,506 shares | -14% | |
| 27Weak | Cerevel Therapeutics Holdings, Inc. | John Renger Chief Scientific Officer | $90k 2,161 shares | -25% | |
| 40Moderate | Cerevel Therapeutics Holdings, Inc. | N Anthony Coles director | $2.1M 50,000 shares | -95% | |
| 21Weak | Cerevel Therapeutics Holdings, Inc. | Ramiro Sanchez Chief Medical Officer | $425k 10,000 shares | -41% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.